SCHEMBL26606975

SCHEMBL26606975

COc1cc(F)cc2[nH]c(-c3ccc(C(C)(C)C)cc3C)cc(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.37
▸ HPGD P15428 4/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ AHR P35869 1/20 0.37
▸ MEN1 O00255 5/20 0.36
▸ KMT2A Q03164 5/20 0.36
▸ THRB P10828 1/20 0.36
▸ IMPDH2 P12268 2/20 0.35
▸ MAPT P10636 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ CYP26A1 O43174 1/20 0.33
▸ CYP26B1 Q9NR63 1/20 0.33
▸ CYP1A1 P04798 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ LOX P28300 1/20 0.32
▸ LOXL3 P58215 1/20 0.32
▸ LOXL2 Q9Y4K0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26607161 0.90 ALDH1A1 (0.35) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL30572993 0.90 ALDH1A1 (0.35) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL26725226 0.87 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL26607281 0.86 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL26725501 0.84 ALDH1A1 (0.36) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL26607069 0.84 ALDH1A1 (0.34) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL26607039 0.84 POLH (0.41) ALDH1A1HPGDKDM4EAHRMEN1
SCHEMBL26606984 0.84 ALDH1A1 (0.37) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL26725110 0.82 ALDH1A1 (0.36) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL26725222 0.81 MEN1 (0.35) ALDH1A1HPGDKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 ALDH1A1 1762/4885HPGD 546/4885KDM4E 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback